Laevoroc

Laevoroc is a Swiss clinical-stage biopharmaceutical group dedicated to the development of innovative therapies for oncology and immunology. The company operates through a decentralized model with specialized entities—Laevoroc Oncology, Laevoroc Chemotherapy, and Laevoroc Immunology—each focusing on distinct therapeutic strategies. Its lead candidate, LR06, is an optimized purine nucleoside analog designed to improve the treatment of hematological malignancies such as chronic lymphocytic leukemia. Laevoroc's approach involves refining proven pharmacological classes to enhance efficacy and safety, targeting significant unmet needs in the global healthcare market. Headquartered in Zug, Switzerland, the company is led by a team of experienced oncology experts and drug developers.